View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 21, 2022

Avrobio receives FDA rare pediatric disease status for cystinosis therapy

AVR-RD-04 is the company's second gene therapy programme to receive this status.

Avrobio has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, AVR-RD-04, designed to treat cystinosis.

AVR-RD-04 works by genetically modify a patient’s hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein. Cystinosis patients have a high deficiency of this protein.

Having earlier obtained orphan drug designation from the regulatory agency, AVR-RD-04 is now the company’s second gene therapy programme to receive rare pediatric disease status.

According to initial findings from the Phase I/II clinical trial, which is underway at the University of California San Diego, the therapy was found to be well tolerated.

Additionally, no adverse events (AEs) linked to the drug have been reported so far. 

All AEs seen were linked to myeloablative conditioning, stem cell mobilisation, underlying ailment or already existing conditions. 

According to the clinical findings obtained so far, the investigational approach was shown to offer benefits in various tissues assessed, including the eyes, skin, gastrointestinal mucosa and neurocognitive system. 

The FDA’s rare pediatric disease designation and Voucher Program aid the development of new drugs and biologics to prevent and treat rare paediatric ailments. 

If a company is approved for New Drug Application (NDA) or Biologics License Application (BLA) for a rare pediatric disease, they can get a voucher for priority review of a later marketing application for another product.

A rare and fatal ailment, cystinosis is characterised by cystine buildup in cellular organelles called lysosomes. 

It leads to progressive damage to various organs, including early, acute kidney disease advancing to end-stage kidney disease.

In July, Avrobio obtained orphan drug designation from the US FDA for AVR-RD-05 to treat mucopolysaccharidosis type II (MPSII) or Hunter syndrome.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology